197 related articles for article (PubMed ID: 29333623)
21. Immunohistochemistry, Molecular Biology, and Clinical Scoring for the Detection of Muir-Torre Syndrome in Cutaneous Sebaceous Tumors: Which Strategy?
Sinson H; Karayan-Tapon L; Godet J; Rivet P; Alleyrat C; Battistella M; Pierron H; Morel F; Lecron JC; Favot L; Frouin E
Dermatology; 2023; 239(6):889-897. PubMed ID: 37717564
[TBL] [Abstract][Full Text] [Related]
22. Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome.
Ponti G; Manfredini M; Pellacani G; Tomasi A
Clin Chem Lab Med; 2016 Nov; 54(11):1725-1731. PubMed ID: 27016151
[TBL] [Abstract][Full Text] [Related]
23. MSH-6: extending the reliability of immunohistochemistry as a screening tool in Muir-Torre syndrome.
Chhibber V; Dresser K; Mahalingam M
Mod Pathol; 2008 Feb; 21(2):159-64. PubMed ID: 18065960
[TBL] [Abstract][Full Text] [Related]
24. Universal immunohistochemical screening of sebaceous neoplasms for Muir-Torre syndrome: Putting the cart before the horse?
Kim RH; Nagler AR; Meehan SA
J Am Acad Dermatol; 2016 Nov; 75(5):1078-1079. PubMed ID: 27745640
[No Abstract] [Full Text] [Related]
25. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm.
Abbas O; Mahalingam M
J Cutan Pathol; 2009 Jun; 36(6):613-9. PubMed ID: 19515040
[TBL] [Abstract][Full Text] [Related]
27. [Muir-Torre syndrome associated with Waldenstrom's macroglobulinemia].
Velter C; Bourlond F; Wettle C; Lioure B; Lipsker D; Maugard C; Cribier B
Ann Dermatol Venereol; 2016 Dec; 143(12):825-830. PubMed ID: 27771121
[TBL] [Abstract][Full Text] [Related]
28. Extraocular well-differentiated sebaceous tumors with overlying cutaneous horns: four tumors in three patients.
Jhuang JY; Liao SL; Tsai JH; Chang HC; Kuo KT; Liau JY
J Cutan Pathol; 2014 Aug; 41(8):650-6. PubMed ID: 24548110
[TBL] [Abstract][Full Text] [Related]
29. Somatic MMR gene mutations as a cause for MSI-H sebaceous neoplasms in Muir-Torre syndrome-like patients.
Joly MO; Attignon V; Saurin JC; Desseigne F; Leroux D; Martin-Denavit T; Giraud S; Bonnet-Dupeyron MN; Faivre L; Auclair J; Grand-Masson C; Audoynaud C; Wang Q
Hum Mutat; 2015 Mar; 36(3):292-5. PubMed ID: 25504677
[TBL] [Abstract][Full Text] [Related]
30. A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome.
Roberts ME; Riegert-Johnson DL; Thomas BC; Rumilla KM; Thomas CS; Heckman MG; Purcell JU; Hanson NB; Leppig KA; Lim J; Cappel MA
Genet Med; 2014 Sep; 16(9):711-6. PubMed ID: 24603434
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic Comparison of Lynch Syndrome-associated and "Lynch-like" Endometrial Carcinomas Identified on Universal Screening Using Mismatch Repair Protein Immunohistochemistry.
Mills AM; Sloan EA; Thomas M; Modesitt SC; Stoler MH; Atkins KA; Moskaluk CA
Am J Surg Pathol; 2016 Feb; 40(2):155-65. PubMed ID: 26523542
[TBL] [Abstract][Full Text] [Related]
32. Patients with a new-onset cutaneous sebaceous neoplasm following immunosuppression should be evaluated for Muir-Torre syndrome with germline mismatch repair gene mutation analysis: case reports.
Cohen PR; Kurzrock R
Dermatol Online J; 2024 Mar; 30(1):. PubMed ID: 38762859
[TBL] [Abstract][Full Text] [Related]
33. MSH6 mutation in a family affected by Muir-Torre syndrome.
Kacerovska D; Cerna K; Martinek P; Grossmann P; Michal M; Ricar J; Kazakov DV
Am J Dermatopathol; 2012 Aug; 34(6):648-52. PubMed ID: 22814321
[TBL] [Abstract][Full Text] [Related]
34. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
35. Muir-Torre syndrome.
Lachiewicz AM; Wilkinson TM; Groben P; Ollila DW; Thomas NE
Am J Clin Dermatol; 2007; 8(5):315-9. PubMed ID: 17902735
[TBL] [Abstract][Full Text] [Related]
36. Muir-Torre syndrome: Diagnostic and screening guidelines.
Jones B; Oh C; Mangold E; Egan CA
Australas J Dermatol; 2006 Nov; 47(4):266-9. PubMed ID: 17034469
[TBL] [Abstract][Full Text] [Related]
37. Sebaceous gland tumors of the eyelids and conjunctiva in the Muir-Torre syndrome: a clinicopathologic study of five cases and literature review.
Rishi K; Font RL
Ophthalmic Plast Reconstr Surg; 2004 Jan; 20(1):31-6. PubMed ID: 14752307
[TBL] [Abstract][Full Text] [Related]
38. Review of the current medical literature and assessment of current utilization patterns regarding mismatch repair protein immunohistochemistry in cutaneous Muir-Torre syndrome-associated neoplasms.
Lee JB; Litzner BR; Vidal CI
J Cutan Pathol; 2017 Nov; 44(11):931-937. PubMed ID: 28749576
[TBL] [Abstract][Full Text] [Related]
39. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
40. [Sebaceous tumors and Muir-Torre syndrome].
Bourlond F; Cribier B; Lipsker D; Velter C
Ann Dermatol Venereol; 2015; 142(6-7):456-9. PubMed ID: 25890836
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]